Search results for "Aminobutyrates"

showing 10 items of 23 documents

Priming: getting ready for battle

2006

International audience; Infection of plants by necrotizing pathogens or colonization of plant roots with certain beneficial microbes causes the induction of a unique physiological state called “priming.” The primed state can also be induced by treatment of plants with various natural and synthetic compounds. Primed plants display either faster, stronger, or both activation of the various cellular defense responses that are induced following attack by either pathogens or insects or in response to abiotic stress. Although the phenomenon has been known for decades, most progress in our understanding of priming has been made over the past few years. Here, we summarize the current knowledge of p…

0106 biological sciencesInsectaPhysiology[SDV]Life Sciences [q-bio]beta-Aminobutyric acidPriming (agriculture)01 natural sciencesPlant Physiological Phenomenachemistry.chemical_compoundsalicylic acid.ethylenePlant biology (Botany)0303 health sciencesAminobutyratesJasmonic acidfood and beveragesGeneral MedicinePlantsLife sciencesmycorrhizal fungimycorhizeBiologieSignal Transductionacide jasmoniquesalicylic acidBiologyMicrobiology03 medical and health sciencesβ-aminobutyric acidMycorrhizal fungiAnimalsβ-aminobutyric acid;bacterial lipopolysaccharides;ethylene;jasmonic acid;mycorrhizal fungi;salicylic acid.Plant Physiological Phenomena030304 developmental biologyacide aminobutyriquePlant rootsAbiotic stressjasmonic acidfungiEthylenesCellular defenseImmunity Innateß-aminobutyric acidbacterial lipopolysaccharideschemistryéthylènefungiAgronomy and Crop Science010606 plant biology & botanyMolecular Plant-Microbe Interactions
researchProduct

Herbicide glufosinate inhibits yeast growth and extends longevity during wine fermentation.

2017

Glufosinate ammonium (GA) is a widely used herbicide that inhibits glutamine synthetase. This inhibition leads to internal amino acid starvation which, in turn, causes the activation of different nutrient sensing pathways. GA also inhibits the enzyme of the yeast Saccharomyces cerevisiae in such a way that, although it is not used as a fungicide, it may alter yeast performance in industrial processes like winemaking. We describe herein how GA indeed inhibits the yeast growth of a wine strain during the fermentation of grape juice. In turn, GA extends longevity in a variety of growth media. The biochemical analysis indicates that GA partially inhibits the nutrient sensing TORC1 pathway, whic…

0301 basic medicineSaccharomyces cerevisiae ProteinsSaccharomyces cerevisiaelcsh:MedicineWineSaccharomyces cerevisiaeProtein Serine-Threonine KinasesArticle03 medical and health scienceschemistry.chemical_compoundGlutamine synthetaselcsh:ScienceAmino acid synthesisWinemakingchemistry.chemical_classificationFermentation in winemakingMultidisciplinarybiologyHerbicidesAminobutyrateslcsh:Rbiology.organism_classificationYeast030104 developmental biologychemistryBiochemistryGlufosinateFermentationlcsh:QFermentationTranscription FactorsScientific reports
researchProduct

Regeneration of herbicide-tolerant black locust transgenic plants by SAAT

2003

A protocol based on SAAT (sonication-assisted Agrobacterium-mediated transformation) has been developed to obtain herbicide-resistant transgenic black locust (Robinia pseudoacacia L.) plants. Cotyledon explants were co-cultivated with Agrobacterium AGL1 strain carrying the pTAB16 plasmid (bar and gusA genes). The effects of bacterial concentration (OD550 of 0.3, 0.6, 0.8) and method of infection (sonication vs immersion) on bacterial delivery were determined by assaying cotyledons for transient beta-glucuronidase expression 3 days after infection. SAAT increases transient expression efficiency especially at an OD550 of 0.6. After determining bacterial concentration and infection method, oth…

Acetosyringonefood.ingredientAgrobacteriumPlant ScienceGenetically modified cropsBiologySonicationchemistry.chemical_compoundTransformation GeneticfoodBotanyRegenerationGlucuronidaseAminobutyratesRobiniafood and beveragesGeneral MedicinePlants Genetically Modifiedbiology.organism_classificationCulture MediaPlant LeavesTransformation (genetics)chemistryShootCotyledonAgronomy and Crop ScienceCotyledonRhizobiumExplant cultureTransformation efficiencyPlant Cell Reports
researchProduct

Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

2015

Background— Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events. Little is known about the effect of drugs on the risk of clinical deterioration in surviving patients. Methods and Results— We compared the angiotensin-neprilysin inhibitor LCZ696 (400 mg daily) with the angiotensin-converting enzyme inhibitor enalapril (20 mg daily) in 8399 patients with heart failure and reduced ejection fraction in a double-blind trial. The analyses focused on prespecified measures of nonfatal clinical deterioration. In comparison with the enalapril group, fewer LCZ696-treated patients required intensification of med…

Angiotensin receptorVascular damage Radboud Institute for Health Sciences [Radboudumc 16]receptorsTetrazolesheart failureAngiotensin-Converting Enzyme InhibitorsKaplan-Meier EstimateSacubitrilAngiotensin; Heart failure; Neprilysin; Receptors; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Double-Blind Method; Enalapril; Heart Failure; Humans; Kaplan-Meier Estimate; Natriuretic Peptide Brain; Neprilysin; Peptide Fragments; Risk Factors; Stroke Volume; Survivors; Tetrazoles; Treatment Outcome; Troponin; Disease Progression; Medicine (all); Cardiology and Cardiovascular Medicine; Physiology (medical)AngiotensinEnalaprilRisk FactorsEnalapril/therapeutic useNatriuretic Peptide BrainHeart Failure/bloodSurvivorsReceptorNeprilysinAminobutyrates: Systèmes cardiovasculaire & respiratoire [D03] [Sciences de la santé humaine]Troponin/bloodTroponinAngiotensin Receptor Antagonists/therapeutic useDrug CombinationsAngiotensin-Converting Enzyme Inhibitors/therapeutic useTreatment OutcomeTetrazoles/therapeutic useCardiologyDisease ProgressionValsartanNeprilysinHeart Failure/blood/drug therapy/physiopathologyCardiology and Cardiovascular Medicinemedicine.drugReceptormedicine.medical_specialtyHeart failureneprilysinAngiotensin Receptor Antagonistsreceptors angiotensinDouble-Blind MethodPhysiology (medical)Internal medicineRenin–angiotensin systemmedicineHumansheart failure neprilysin receptors angiotensinEnalaprilbusiness.industryBiphenyl CompoundsStroke Volumemedicine.diseasePeptide FragmentsEndocrinologyAminobutyrates/therapeutic useStroke Volume/physiologyHeart failureNatriuretic Peptide Brain/blood: Cardiovascular & respiratory systems [D03] [Human health sciences]businessNeprilysin/antagonists & inhibitorsPeptide Fragments/bloodSacubitril ValsartanBiomarkersBiomarkers/blood
researchProduct

NEUROCHEMICAL STUDIES WITH L-CYCLOSERINE, A CENTRAL DEPRESSANT AGENT.

1963

CerebellumCarboxy-LyasesThalamusCaudate nucleusPharmacologyBiochemistryAminobutyric acidCellular and Molecular Neurosciencechemistry.chemical_compoundMiceNeurochemicalThalamusMesencephalonCerebellummedicineAnimalsPyridoxal phosphateEnzyme InhibitorsTransaminasesCerebral CortexPharmacologyAminobutyratesResearchCycloserineBrainNeurochemistryElectrophysiologymedicine.anatomical_structurechemistryCerebral cortexCycloserinePyridoxal PhosphateCaudate Nucleusmedicine.drugBrain StemJournal of neurochemistry
researchProduct

Enhanced tonic GABAA inhibition in typical absence epilepsy

2009

The cellular mechanisms underlying typical absence seizures, which characterize various idiopathic generalized epilepsies, are not fully understood, but impaired γ-aminobutyric acid (GABA)-ergic inhibition remains an attractive hypothesis. In contrast, we show here that extrasynaptic GABAA receptor–dependent 'tonic' inhibition is increased in thalamocortical neurons from diverse genetic and pharmacological models of absence seizures. Increased tonic inhibition is due to compromised GABA uptake by the GABA transporter GAT-1 in the genetic models tested, and GAT-1 is crucial in governing seizure genesis. Extrasynaptic GABAA receptors are a requirement for seizures in two of the best character…

GABA Plasma Membrane Transport ProteinsGABA Plasma Membrane Transport ProteinsCellular pathologystargazerBiologyPharmacologytonic currentSettore BIO/09 - FisiologiaArticleGeneral Biochemistry Genetics and Molecular BiologyTonic (physiology)spike–and–wave discharge03 medical and health sciencesEpilepsy0302 clinical medicineThalamusthalamusGenetic modelmedicineAnimalsGABA transporterGABA-A Receptor AntagonistsReceptorTHIP030304 developmental biology0303 health sciencesextrasynaptic tonic current GAT–1 thalamus spike–and–wave discharge GAERS stargazer lethargic GHB THIPGABAA receptorAminobutyratesPetit mal epilepsyGeneral Medicineextrasynapticmedicine.diseaseReceptors GABA-ARats3. Good healthEpilepsy Absenceabsence epilepsy GABA electrophysiology patch clampnervous systemGAT–1GAERSbiology.proteinlethargicGHB030217 neurology & neurosurgery
researchProduct

Conformational Properties of Oxazole-Amino Acids: Effect of the Intramolecular N–H···N Hydrogen Bond

2014

Oxazole ring occurs in numerous natural peptides, but conformational properties of the amino acid residue containing the oxazole ring in place of the C-terminal amide bond are poorly recognized. A series of model compounds constituted by the oxazole-amino acids occurring in nature, that is, oxazole-alanine (L-Ala-Ozl), oxazole-dehydroalanine (ΔAla-Ozl), and oxazole-dehydrobutyrine ((Z)-ΔAbu-Ozl), was investigated using theoretical calculations supported by FTIR and NMR spectra and single-crystal X-ray diffraction. It was found that the main feature of the studied oxazole-amino acids is the stable conformation β2 with the torsion angles φ and ψ of -150°, -10° for L-Ala-Ozl, -180°, 0° for ΔAl…

Magnetic Resonance SpectroscopyDouble bondNitrogenSurface PropertiesStereochemistryMolecular Conformation010402 general chemistry01 natural scienceschemistry.chemical_compoundSpectroscopy Fourier Transform InfraredMaterials ChemistryPeptide bondAmino AcidsPhysical and Theoretical ChemistryOxazolesOxazolechemistry.chemical_classificationAlanine010405 organic chemistryHydrogen bondAminobutyratesHydrogen BondingNuclear magnetic resonance spectroscopyModels Theoretical0104 chemical sciencesSurfaces Coatings and FilmsAmino acidNMR spectra databasechemistryIntramolecular forceSolventsThermodynamicsHydrogenThe Journal of Physical Chemistry B
researchProduct

Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?

2021

BackgroundCirculating Neprilysin (sNEP) has emerged as a potential prognostic biomarker in heart failure (HF). In PARAGON-HF benefit of sacubitril/valsartan was only observed in patients with left ventricular ejection fraction (LVEF) ≤57%. We aimed to assess the prognostic value of sNEP in outpatients with HF and LVEF >57%, in comparison with patients with LVEF ≤57%.MethodsConsecutive HF outpatients were included from May-2006 to February-2016. The primary endpoint was the composite of all-cause death or HF hospitalization and the main secondary endpoint was the composite of cardiovascular death or HF hospitalization. For the later competing risk methods were used.ResultssNEP was measure…

MalePhysiologyCancer TreatmentCardiovascular MedicineBiochemistrySacubitrilMedical ConditionsClinical endpointMedicine and Health SciencesMultidisciplinaryEjection fractionPharmaceuticsAminobutyratesHazard ratioQRMiddle AgedPrognosisBody FluidsCardiovascular TherapyBloodValsartanOncologyCardiovascular DiseasesCardiologycardiovascular systemMedicineValsartanFemaleNeprilysinAnatomymedicine.drugcirculatory and respiratory physiologyResearch Articlemedicine.medical_specialtyScienceCardiologyDrug TherapyInternal medicinemedicineHumanscardiovascular diseasesAgedProportional Hazards ModelsHeart FailureProportional hazards modelbusiness.industryBiphenyl CompoundsBiology and Life SciencesStroke VolumeCardiovascular Disease Riskmedicine.diseaseHeart failurebusinessSacubitril ValsartanBiomarkersReceptor Antagonist TherapyEjection FractionPloS one
researchProduct

A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure

2015

Aims: Although active-controlled trials with renin–angiotensin inhibitors are ethically mandated in heart failure with reduced ejection fraction, clinicians and regulators often want to know how the experimental therapy would perform compared with placebo. The angiotensin receptor-neprilysin inhibitor LCZ696 was compared with enalapril in PARADIGM-HF. We made indirect comparisons of the effects of LCZ696 with putative placebos.\ud \ud Methods and results: We used the treatment-arm of the Studies Of Left Ventricular Dysfunction (SOLVD-T) as the reference trial for comparison of an ACE inhibitor to placebo and the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidit…

MaleTetrazolesAngiotensin-Converting Enzyme InhibitorsEnalaprilEnalapril/therapeutic useMedicineNatriuretic peptidesAngiotensin IIAminobutyratesHeart Failure/CardiomyopathyMiddle AgedAngiotensin Receptor Antagonists/therapeutic useHospitalizationAngiotensin-Converting Enzyme Inhibitors/therapeutic useDrug CombinationsTreatment OutcomeTetrazoles/therapeutic useCardiologyValsartanFemaleCardiology and Cardiovascular Medicinemedicine.drugBenzimidazoles/therapeutic usemedicine.medical_specialtyAngiotensin II Type 1 Receptor Blockers/therapeutic usemedicine.drug_classPlaceboAngiotensin Receptor AntagonistsInternal medicineHumansEnalaprilFASTTrack Clinical ResearchBeta blockerAgedHospitalization/statistics & numerical dataHeart Failurebusiness.industryBiphenyl Compoundsmedicine.diseaseHeart Failure/drug therapyPlacebo EffectAngiotensin IICandesartanEndocrinologyAminobutyrates/therapeutic useHeart failureACE inhibitorBenzimidazolesbusinessAngiotensin II Type 1 Receptor BlockersSacubitril ValsartanNatriuretic peptide
researchProduct

Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients.

2022

Purpose Only a few studies are available on dose-related effects of sacubitril/valsartan (angiotensin receptor neprilysin inhibition (ARNI)) in real-life patients with heart failure and reduced ejection fraction (HFrEF). We sought to investigate clinical and functional effects in real-life HFrEF patients receiving ARNI at a different cumulative dose. Methods This was an observational study in consecutive outpatients admitted for HFrEF from October 2017 to June 2019. The PARADIGM criteria were needed for enrolment. ARNI was uptitrated according to blood pressure, drug tolerability, renal function and kaliemia. At least 10-month follow-up was required in each patient. Clinical assessment, Kan…

Malemedicine.medical_specialtyARNIBlood PressureWalk TestComorbiditySacubitrilVentricular Function LeftAngiotensin Receptor AntagonistsInternal medicinemedicine6-min walking test Aged Aminobutyrates Angiotensin Receptor Antagonists ARNI Biphenyl Compounds Blood Pressure Comorbidity Dose-Response Relationship Drug Drug Combinations Echocardiography Female Heart failure Humans Left ventricular function Male Middle Aged Prospective Studies Sacubitril/valsartan Stroke Volume Valsartan Ventricular Function Left Walk TestHumansPharmacology (medical)Sacubitril/valsartanProspective Studies6-min walking testAgedPharmacologyHeart FailureEjection fractionDose-Response Relationship DrugCumulative dosebusiness.industryAminobutyratesLeft ventricular functionBiphenyl CompoundsStroke VolumeGeneral MedicineMiddle Agedmedicine.diseaseClinical TrialARNI heart failure left ventricular function 6-minutes walking test Sacubitril/valsartan.Drug CombinationsBlood pressureTolerabilityValsartanEchocardiographyHeart failureCardiologyValsartanFemalebusinessSacubitril Valsartanmedicine.drugEuropean journal of clinical pharmacology
researchProduct